Vinorelbine
- Generic Name
- Vinorelbine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C45H54N4O8
- CAS Number
- 71486-22-1
- Unique Ingredient Identifier
- Q6C979R91Y
- Background
Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) . It was initially approved in the USA in 1990's for the treatment of NSCLC .
...
- Indication
Vinorelbine tartrate is indicated for adults in the treatment of advanced non-small cell lung cancer (NSCLC), as a single therapy or in combination with other chemotherapeutic drugs .
Used in relapsed or refractory Hodgkin lymphoma, in combination with other chemotherapy agents .
...
- Associated Conditions
- Locally Advanced Non-Small Cell Lung Cancer, Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Non-Small Cell Lung Cancer, Recurrent Cervical Cancer, Soft Tissue Sarcoma
- Associated Therapies
- -
Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2009-02-12
- Last Posted Date
- 2017-01-13
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 232
- Registration Number
- NCT00842712
- Locations
- 🇪🇸
Research Site, Barcelona, Spain
A Feasibility Trial of Avastin (Bevacizumab) in Combination With Concomitant Chemoradiation (Cisplatin and Vinorelbine) in Patients With Locally Advanced Non-Squamous Non-Small Cell Lung Cancer.
- Conditions
- Interventions
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 6
- Registration Number
- NCT00773188
Vinorelbine Metronomic Plus Lapatinib for Overexpressing HER-2 Metastatic Breast Cancer
- First Posted Date
- 2008-09-18
- Last Posted Date
- 2015-09-28
- Lead Sponsor
- University Hospital of Crete
- Target Recruit Count
- 16
- Registration Number
- NCT00754702
- Locations
- 🇬🇷
"IASO" General Hospital of Athens, 1st Dep of Medical Oncology, Athens, Greece
🇬🇷University Hospital of Crete, Dep of Medical Oncology, Heraklion, Crete, Greece
Metronomic Vinorelbine and Bevacizumab in Patients With Non Small Cell Lung Cancer
- First Posted Date
- 2008-09-18
- Last Posted Date
- 2016-10-04
- Lead Sponsor
- Hellenic Oncology Research Group
- Target Recruit Count
- 48
- Registration Number
- NCT00755170
- Locations
- 🇬🇷
University Hospital of Crete, Dep of Medical Oncology, Heraklion, Greece
🇬🇷"IASO" General Hospital of Athens, 1st Dep of Medical Oncology, Athens, Greece
🇬🇷University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece
Vinorelbine/Gemcitabine Versus Vinorelbine/Carboplatin in Advanced Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-08-20
- Last Posted Date
- 2011-04-04
- Lead Sponsor
- The Norwegian Lung Cancer Study Group
- Target Recruit Count
- 444
- Registration Number
- NCT00737867
- Locations
- 🇳🇴
Øystein Fløtten, Bergen, Norway
🇳🇴Sverre Fluge, Haugesund, Norway
🇳🇴Tore Amundsen, Trondheim, Norway
Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine and Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer
- Conditions
- First Posted Date
- 2008-07-29
- Last Posted Date
- 2014-03-07
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 26
- Registration Number
- NCT00724386
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-06-27
- Last Posted Date
- 2018-08-09
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 92
- Registration Number
- NCT00706030
- Locations
- 🇺🇸
Albert Einstein Cancer Center, Bronx, New York, United States
🇫🇷Centre Paul Papin, Angers, France
🇪🇸Centro Oncologico de Galicia, A Coruña, Spain
Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-06-26
- Last Posted Date
- 2013-02-13
- Lead Sponsor
- Hellenic Oncology Research Group
- Target Recruit Count
- 88
- Registration Number
- NCT00705549
- Locations
- 🇬🇷
Sotiria" General Hospital, 1st, 3rd, 8th Dep of Pulmonary Diseases, Athens, Greece
🇬🇷"Metaxa's" Anticancer Hospital of Piraeus,1st Dep of Medical Oncology, Piraeus, Greece
🇬🇷"Theagenion" Anticancer Hospital of Thessaloniki, Thessaloniki, Greece
Vinorelbine Metronomic Plus Bevacizumab as Salvage Therapy for Breast Cancer
- First Posted Date
- 2008-06-10
- Last Posted Date
- 2015-05-29
- Lead Sponsor
- Hellenic Oncology Research Group
- Target Recruit Count
- 13
- Registration Number
- NCT00694200
- Locations
- 🇬🇷
University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece
🇬🇷"IASO" General Hospital of Athens, 1st Dep of Medical Oncology, Athens, Greece
🇬🇷"Laikon" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, Greece
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2016-06-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 598
- Registration Number
- NCT00686959
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.